- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Patent holdings for IPC class C07D 413/06
Total number of patents in this class: 2162
10-year publication summary
|
160
|
125
|
149
|
156
|
137
|
96
|
110
|
134
|
119
|
90
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Takeda Pharmaceutical Company Limited | 2721 |
52 |
| VALO Health, Inc. | 176 |
51 |
| Merck Sharp & Dohme LLC | 3732 |
50 |
| Janssen Pharmaceutica N.V. | 3358 |
41 |
| F. Hoffmann-La Roche AG | 7937 |
40 |
| Boehringer Ingelheim International GmbH | 4636 |
39 |
| Bristol-myers Squibb Company | 4826 |
35 |
| Novartis AG | 10612 |
26 |
| Merck Patent GmbH | 5752 |
23 |
| Achillion Pharmaceuticals, Inc. | 164 |
23 |
| Hoffmann-La Roche Inc. | 3546 |
22 |
| Incyte Corporation | 1039 |
19 |
| AstraZeneca AB | 2857 |
18 |
| Gilead Sciences, Inc. | 2106 |
18 |
| Pfizer Inc. | 3401 |
17 |
| Abbvie Inc. | 1817 |
16 |
| The Regents of the University of California | 20303 |
14 |
| Amgen Inc. | 4256 |
14 |
| ChemoCentryx, Inc. | 379 |
14 |
| Global Blood Therapeutics, Inc. | 183 |
14 |
| Other owners | 1616 |